Skip to content
2000
Volume 1, Issue 1
  • ISSN: 2210-299X
  • E-ISSN: 2210-3007
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

The purpose of the study was to investigate the role of the endocannabinoid system and the therapeutic potential benefits of cannabinoids in Alzheimer’s disease. The most frequent form of dementia in older individuals is Alzheimer's disease (AD), a progressive neurological ailment that gradually deprives people of their memory, cognitive abilities, and, ultimately, their ability to perform daily tasks. Alzheimer's disease is distinguished by a progressive deterioration in cognitive function, which includes a decline in memory, learning capacity, and thinking power. The human body's endocannabinoid system functions as a channel for cell communication. It is a neurotransmission system that is present in various regions of the body and tissues as well as assists in the control of a number of metabolic processes. Endocannabinoids, enzymes, and cannabinoid receptors all play a role in managing a variety of biological functions. In this review, we aimed to summarize the endocannabinoid system, the effect of beta-amyloid, tau-protein accumulation and neuroinflammation, potential therapeutic benefits of cannabinoids, current pre-clinical and clinical evidence for the potential therapeutic benefits, limitations, and challenges, and potential future research in the field. Emerging scientific data suggests that the is linked to neurodegenerative illnesses and that altering its tone may be a useful therapeutic strategy for the treatment of AD (Alzheimer’s disease).

© 2023 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cis/10.2174/012210299X256030231114114815
2023-01-01
2025-11-12

  • From This Site

    /content/journals/cis/10.2174/012210299X256030231114114815
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cis/1/1/CIS-1-E2210299X256030.html?itemId=/content/journals/cis/10.2174/012210299X256030231114114815&mimeType=html&fmt=ahah

References

  1. ChiromaS.M. BaharuldinM.T.H. TaibC.N.M. AmomZ. JagadeesanS. MoklasM.A.M. Inflammation in Alzheimer’s disease: A friend or foe?Biomed. Res. Ther.2018582552256410.15419/bmrat.v5i8.464
     [Google Scholar]
  2. Kumar ThakurA. KambojP. GoswamiK. AhujaK. Pathophysiology and management of alzheimer’s disease: An overview.J. Anal. Pharm. Res.20187210.15406/japlr.2018.07.00230
     [Google Scholar]
  3. AbateG. UbertiD. TambaroS. Potential and limits of cannabinoids in alzheimer’s disease therapy.Biology202110654210.3390/biology1006054234204237
     [Google Scholar]
  4. AsoE. FerrerI. Cannabinoids for treatment of Alzheimer’s disease: Moving toward the clinic.Front. Pharmacol.201453710.3389/fphar.2014.0003724634659
     [Google Scholar]
  5. RuthirakuhanM. HerrmannN. AndreazzaA.C. VerhoeffN.P.L.G. GallagherD. BlackS.E. KissA. LanctôtK.L. Agitation, oxidative stress, and cytokines in Alzheimer disease: biomarker analyses from a clinical trial with nabilone for agitation.J. Geriatr. Psychiatry Neurol.202033417518410.1177/089198871987411831547752
     [Google Scholar]
  6. ZhangS.S. ZhangN.N. GuoT.T. SheenL.Y. HoC.T. BaiN.S. The impact of phyto- and endo-cannabinoids on central nervous system diseases: A review.J. Tradit. Complement. Med.2023131303810.1016/j.jtcme.2022.10.00436685079
     [Google Scholar]
  7. JacobsJ.A. SehgalA. Anandamide metabolites protect against seizures through the TRP channel water witch in Drosophila melanogaster.Cell Rep.202031910771010.1016/j.celrep.2020.10771032492422
     [Google Scholar]
  8. Ibarra-LecueI. Pilar-CuéllarF. MuguruzaC. Florensa-ZanuyE. DíazÁ. UrigüenL. CastroE. PazosA. CalladoL.F. The endocannabinoid system in mental disorders: Evidence from human brain studies.Biochem. Pharmacol.20181579710710.1016/j.bcp.2018.07.00930026022
     [Google Scholar]
  9. TudoranceaI.M. CiorpacM. StanciuG.D. CaratașuC. SăcărescuA. IgnatB. BurluiA. RezușE. CreangăI. Alexa-StratulatT. TudoranceaI. TambaB.I. The therapeutic potential of the endocannabinoid system in age-related diseases.Biomedicines20221010249210.3390/biomedicines1010249236289755
     [Google Scholar]
  10. Available from: https://www.medicalnewstoday.com/articles/endocannabinoid (Accessed on February 21, 2023).
  11. Available from: https://svrhemp.com/what-is-the-endocannabinoid-system/ (Accessed on February 21, 2023).
  12. Available from: https://www.kalapa-clinic.com/en/endocannabinoid-system/ (Accessed on February 21, 2023).
  13. LuH.C. MackieK. An introduction to the endogenous cannabinoid system.Biol. Psychiatry201679751652510.1016/j.biopsych.2015.07.02826698193
     [Google Scholar]
  14. Available from: https://www.healthline.com/health/endocannabinoid-system#how-it-works (Accessed on February 21 2023).
  15. HowlettA.C. BarthF. BonnerT.I. CabralG. CasellasP. DevaneW.A. FelderC.C. HerkenhamM. MackieK. MartinB.R. MechoulamR. PertweeR.G. International union of pharmacology. XXVII. Classification of cannabinoid receptors.Pharmacol. Rev.200254216120210.1124/pr.54.2.16112037135
     [Google Scholar]
  16. RamirezS.H. HaskóJ. SkubaA. FanS. DykstraH. McCormickR. ReichenbachN. KrizbaiI. MahadevanA. ZhangM. TumaR. SonY.J. PersidskyY. Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions.J. Neurosci.201232124004401610.1523/JNEUROSCI.4628‑11.201222442067
     [Google Scholar]
  17. Available from: https://www.nia.nih.gov/news/sleep-loss-encourages-spread-toxic-alzheimers-protein#:~:text=It%E2%80%99s%20long%20been%20recognized%20that%20Alzheimer%E2%80%99s (Accessed on February 22 2023).
  18. GarbuzD.G. ZatsepinaO.G. Evgen’evM.B. [Beta Amyloid, Tau Protein, and Neuroinflammation: An Attempt to Integrate Different Hypotheses of Alzheimer’s Disease Pathogenesis].Mol. Biol. (Mosk.)202155573474734671002
     [Google Scholar]
  19. HeppnerF.L. RansohoffR.M. BecherB. Immune attack: The role of inflammation in Alzheimer disease.Nat. Rev. Neurosci.201516635837210.1038/nrn388025991443
     [Google Scholar]
  20. Available from: https://www.nia.nih.gov/health/what-happens-brain-alzheimers-disease (Accessed on February 22 2023).
  21. MüllerU.C. DellerT. KorteM. Not just amyloid: Physiological functions of the amyloid precursor protein family.Nat. Rev. Neurosci.201718528129810.1038/nrn.2017.2928360418
     [Google Scholar]
  22. HaassC. SelkoeD.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptide.Nat. Rev. Mol. Cell Biol.20078210111210.1038/nrm210117245412
     [Google Scholar]
  23. KabraA. A Systematic Review of Amyloid-β and Tau’s contribution to Neuroinflammation in Alzheimer's Disease Progression.10.36838/v4i6.10
     [Google Scholar]
  24. BntoN JPThe role of neurofibrillary tangles in Alzheimer disease.Acta neuol. belg.199898165174
     [Google Scholar]
  25. MehtaD. IwamotoK. UedaJ. BundoM. AdatiN. KojimaT. KatoT. Comprehensive survey of CNVs influencing gene expression in the human brain and its implications for pathophysiology.Neurosci. Res.201479223310.1016/j.neures.2013.10.00924211644
     [Google Scholar]
  26. CarmonaS. ZahsK. WuE. DakinK. BrasJ. GuerreiroR. The role of TREM2 in Alzheimer’s disease and other neurodegenerative disorders.Lancet Neurol.201817872173010.1016/S1474‑4422(18)30232‑130033062
     [Google Scholar]
  27. UddinM.S. MamunA.A. SumsuzzmanD.M. AshrafG.M. PerveenA. BungauS.G. MousaS.A. El-SeediH.R. Bin-JumahM.N. Abdel-DaimM.M. Emerging promise of cannabinoids for the management of pain and associated neuropathological alterations in Alzheimer’s disease.Front. Pharmacol.202011109710.3389/fphar.2020.0109732792944
     [Google Scholar]
  28. RamosLauren Therapeutic potential of cannabinoids in the management of Alzheimer's Disease and other neurodegenerative conditionsAvailable from: https://core.ac.uk/download/pdf/286269001.pdf 2019
     [Google Scholar]
  29. KarlT. ChengD. GarnerB. ArnoldJ.C. The therapeutic potential of the endocannabinoid system for Alzheimer’s disease.Expert Opin. Ther. Targets201216440742010.1517/14728222.2012.67181222448595
     [Google Scholar]
  30. ColesM. Steiner-LimG.Z. KarlT. Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer’s disease.Front. Neurosci.20221696292210.3389/fnins.2022.96292236117622
     [Google Scholar]
  31. WattG. KarlT. In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer’s disease.Front. Pharmacol.201782010.3389/fphar.2017.0002028217094
     [Google Scholar]
  32. SirbuCA ManoleAM VasileTM TomaGS DobricanLR VîrvaraDG VasiliuO Cannabinoids–a new therapeutic strategy in neurology.Romanian J.2022125334910.55453/rjmm.2022.125.3.1
     [Google Scholar]
  33. KrishnanS CairnsR HowardR Cannabinoids for the treatment of dementia.Cochrane Database Syst. Rev.20092CD00720410.1002/14651858.CD007204.pub2
     [Google Scholar]
  34. KroonE. KuhnsL. CousijnJ. The short-term and long-term effects of cannabis on cognition: Recent advances in the field.Curr. Opin. Psychol.202138495510.1016/j.copsyc.2020.07.00532823178
     [Google Scholar]
  35. CoorayR. GuptaV. SuphiogluC. Current aspects of the endocannabinoid system and targeted THC and CBD phytocannabinoids as potential therapeutics for Parkinson’s and Alzheimer’s diseases: a review.Mol. Neurobiol.202057114878489010.1007/s12035‑020‑02054‑632813239
     [Google Scholar]
  36. BerryA.J. ZubkoO. ReevesS.J. HowardR.J. Endocannabinoid system alterations in Alzheimer’s disease: A systematic review of human studies.Brain Res.2020174914713510.1016/j.brainres.2020.14713532980333
     [Google Scholar]
  37. BedseG. RomanoA. LavecchiaA.M. CassanoT. GaetaniS. The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer’s disease.J. Alzheimers Dis.20144341115113610.3233/JAD‑14163525147120
     [Google Scholar]
  38. AsoE. JuvésS. MaldonadoR. FerrerI. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice.J. Alzheimers Dis.201335484785810.3233/JAD‑13013723515018
     [Google Scholar]
  39. Available from: https://en.wikipedia.org/wiki/Cannabinol (Accessed on 21 July 2023).
  40. Available from: https://en.wikipedia.org/wiki/Tetrahydrocannabinol (Accessed on 21 July 2023).
/content/journals/cis/10.2174/012210299X256030231114114815
Loading
Potential Therapeutic Role of Cannabinoid System in Alzheimer’s Disease: A Review
Curr. Indian Sci. 1, E2210299X256030 (2023); https://doi.org/10.2174/012210299X256030231114114815
/content/journals/cis/10.2174/012210299X256030231114114815
/content/journals/cis/10.2174/012210299X256030231114114815
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Alzheimer's disease; Beta amyloids; Cannabinoid receptors; Cannabinoids; Endocannabinoid system; Neurodegenerative illnesses

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test